Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.

Prostate

Department of Genitourinary Medical Oncology, The David Koch Center for Applied Research of Genitourinary Cancers, The Stanford Alexander Tissue Derivatives Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA.

Published: November 2012

AI Article Synopsis

  • Hedgehog signaling plays a crucial role in prostate and bone development, and its abnormal activation is linked to aggressive prostate cancer, making it a potential target for therapy.
  • In an experimental study, increased Hedgehog signaling was confirmed in advanced prostate cancer, particularly in bone metastatic cases, and the effects of the Smoothened inhibitor GDC-0449 were tested.
  • Treatment with GDC-0449 showed a decrease in Hedgehog signaling activity and reduced tumor cell proliferation, suggesting that targeting this pathway could offer new therapeutic options for advanced prostate cancer.

Article Abstract

Background: Hedgehog signaling is a stromal-mesenchymal pathway central to the development and homeostasis of both the prostate and the bone. Aberrant Hedgehog signaling activation has been associated with prostate cancer aggressiveness. We hypothesize that Hedgehog pathway is a candidate therapeutic target in advanced prostate cancer. We confirm increased Hedgehog signaling in advanced and bone metastatic castrate resistant prostate cancer and examine the pharmacodynamic effect of Smoothened inhibition by the novel reagent GDC-0449 in an experimental prostate cancer model.

Methods: Hedgehog signaling component expression was assessed in tissue microarrays of high grade locally advanced and bone metastatic disease. Male SCID mice subcutaneously injected with the bone forming xenograft MDA PCa 118b were treated with GDC-0449. Hedgehog signaling in the tumor microenvironment was assessed by proteomic and species specific RNA expression and compared between GDC-0449 treated and untreated animals.

Results: We observe Hedgehog signaling in high grade locally advanced and bone marrow infiltrating disease. Evidence of paracrine activation of Hedgehog signaling in the tumor xenograft, was provided by increased Sonic Hedgehog expression in human tumor epithelial cells, coupled with increased Gli1 and Patched1 expression in the murine stromal compartment, while normal murine stroma did not exhibit Hh signaling expression. GDC-0449 treatment attenuated Hh signaling as evidenced by reduced expression of Gli1 and Ptch1. Reduction in proliferation (Ki67) was observed with no change in tumor volume.

Conclusions: GDC-0449 treatment is pharmacodynamically effective as evidenced by paracrine Hedgehog signaling inhibition and results in tumor cell proliferation reduction. Understanding these observations will inform the clinical development of therapy based on Hedgehog signaling inhibition.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977841PMC
http://dx.doi.org/10.1002/pros.22517DOI Listing

Publication Analysis

Top Keywords

hedgehog signaling
40
prostate cancer
20
hedgehog
12
signaling inhibition
12
advanced bone
12
signaling
11
bone forming
8
xenograft mda
8
mda pca
8
pca 118b
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!